Beyond the political fight over the DoD’s new testosterone screening mandate remains a clinical question: Does population-level screening of a mostly asymptomatic, young military population offer significant benefit or simply raise risk?
Somatic Tumor Risk Assessment Predicts Prostate Cancer Overall Survival
Even though tumor comprehensive genomic profiling (CGP) has revolutionized the care of many cancers and identifies patients for biomarker-specific therapy, it had not been available for all variations.
More Genetic Testing, New Drug Combinations Hold Promise for Prostate Cancer With Germline Variants
Pathogenic germline variants might be found in a relatively small percentage of prostate cancer patients, but they can make the prognosis much, much worse. Now, the future is looking brighter, with the VA and other healthcare systems spearheading more testing. At the same time, drug combinations involving PARP inhibitors are showing some success in lengthening survival.
Docetaxel Rechallenge Shows Promise in Select Patients With mCRPC
For more than two decades, docetaxel has been a cornerstone in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Since its introduction in 2004, it has remained a foundational therapy, later joined by cabazitaxel—another taxane approved in 2010 for patients whose disease progresses after docetaxel.
Comorbidities Linked to Higher Complication Risk After Prostate Cancer Surgery
Men undergoing surgery for prostate cancer often present with more than their malignancy. Many also are managing chronic comorbidities such as cardiovascular disease, diabetes and hypertension.
As Benign Prostatic Hyperplasia Care Evolves, TURP Shows Fewer Complications but More Retreatment
For decades, transurethral resection of the prostate (TURP)—a surgical procedure that removes excess prostate tissue through the urethra to relieve urinary obstruction—has been regarded as the gold standard surgical treatment for benign prostatic hyperplasia (BPH).
How Do Statins Impact Prostate Survival in Veterans?
A new study identified a strong minimum effective dose/duration type relationship with statin use in veterans with prostate cancer receiving androgen deprivation therapy (ADT).
MRI Findings Can Help Stage Prostate Cancer
MRI findings should be considered in prostate cancer staging, according to a new study led by Duke University and the Durham, NC, VA Healthcare System.
MRI Instead of Biopsy in Prostate Cancer Under Active Surveillance Appears to Result in Underdiagnosis
For about three decades, active surveillance (AS) has been the preferred management for favorable-risk prostate cancer (PC) and has traditionally included confirmatory biopsy to address any under sampling at diagnosis.
Making Prostate Cancer Imaging More Guideline Concordant
Inappropriate imaging to stage low-risk prostate cancer is considered low-value care. A new VA study sought to determine the effectiveness of a theory-based intervention, Prostate Cancer Imaging Stewardship (PCIS), to promote guideline-concordant imaging.
Preexisting Depression Worsens Prostate Cancer Survival
Preexisting depression was associated with a 2.5-fold increase in mortality risk for patients with prostate cancer (PCa), exacerbating disease progression and worsening survival, according to a new research letter.
Biomarker Helped Distinguish Prostate Cancer From BPH Only
Is the diagnosis benign prostatic hyperplasia (BPH) or prostate cancer (PCa)?
Osteoporosis Linked to Treated Testicular Cancer, Which Is Common in Young Men
Concerns have been raised about the long-term implications of treatment for testicular cancer (TC), which is the most common malignancy among young males and has cure rates more than 95%.
Racial Differences Found With Metastatic Prostate Cancer Tumors
U.S. veterans with metastatic prostate cancer (mPCa) demonstrate important racial differences in the genetic makeup of tumors, according to a new study, but researchers also found that survival outcomes were similar when care was provided in a nearly equal-access healthcare system.
Testicular Cancer Survivors Have Higher Rates of Metabolic Syndrome
VA patients who are survivors of testicular cancer are significantly more likely to develop metabolic syndrome compared to individuals without a history of testicular cancer, according to a recent study.
Osteoporosis Linked to Treated Testicular Cancer
Concerns have been raised about the long-term implications of treatment for testicular cancer (TC), the most common malignancy among young males with cure rates more than 95%.
PSA Screening History Useful Predictor of Prostate Cancer Risk in Seniors
In men over 70 years old, prostate-specific antigen (PSA) screening history could be a highly informative predictor of long-term risk of prostate cancer by identifying individuals with certain PSA values as very low risk, according to a recent study.
New Studies: BRCA1, BRCA2 Mutations Deserve More Attention in Men
For years, BRCA1 and BRCA2 mutations have been almost exclusively associated with women’s health—particularly breast and ovarian cancers.
‘Prescription Rules’ Could Lengthen Survival in mCRPC
If detected and treated at an early stage, prostate cancer is often curable. That is not the case, however, with an advanced stage such as metastatic castration-resistant prostate cancer (mCRPC), which has a high risk of mortality.
How General Obesity Affects Prostate Cancer
How does general obesity affect prostate cancer? Thus far, inconsistent evidence has been found for the association between general obesity and prostate cancer among men in the United States.
No Problems Found With Concurrent Spironolactone, Abiraterone Administration
The most common cancer in men in the United States, prostate cancer has low survival rates once metastasized.
VA Overtreats Prostate Cancer in Veterans with Limited Life Expectancy
Overtreatment, especially with radiotherapy, has increased for veterans with limited life expectancy and intermediate-risk or high-risk prostate cancer, according to a new study.
Military Service, Race Make Black Veterans More Likely To Have Metastatic Prostate Cancer
The issue of metastasis in prostate cancer can’t really be discussed without a startling fact: Black men are disproportionately affected by prostate cancer (PCa), with earlier presentation, more aggressive disease, and higher mortality rates vs. white men.
VA Continues Research on Radioligands to Optimize Treatment of mCRPC
The promising outcomes from studies of the radioligand lutetium Lu 177 vipivotide tetraxetan (Lu177-PSMA) as a second-line therapy for metastatic castration-resistant prostate cancer (mCRPC) has encouraged researchers to explore its effectiveness when moved earlier in treatment and in combination with other cancer therapies.
Veterans’ Higher Risk of Metastatic Prostate Cancer Drives Continuous Treatment Updates at VA
The U.S. government and the VA increasingly recognize the increased risk of prostate cancer faced by veterans and its relationship to service in areas of conflict.
Consensus Statement, Real-World Experience Guide Lu177-PSMA Use
Since receiving Food and Drug Administration (FDA) approval in 2022 for use in metastatic castration-resistant prostate cancer (mCRPC), adoption of lutetium Lu 177 vipivotide tetraxetan (Lu177-PSMA) has grown rapidly.
Treatment for mCRPC Undergoes Constant Reassessment, Improvement at VA
As the options for treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to increase, determining the best order for sequencing them becomes more complicated.
Alternative Prostate Cancer Screening Guidelines for U.S. Black Men
In the United States, Black men are at highest risk for being diagnosed with and dying from prostate cancer.
Review Authors Urge More Genetic Testing of BRCA for Male Cancer Patients
Even though half of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, the implications for their health tend to be under-recognized compared to females, according to a new study.
Prescription Medications Affect Survival Rates in Metastatic Prostate Cancer
How do prescription medications affect overall survival in metastatic hormone-sensitive prostate cancer?
